Increased urinary excretion of platelet activating factor in mice with lupus nephritis

Macconi, Daniela; Noris, Marina; Benfenati, Emilio; Quaglia, Roberto; Pagliarino, Gianluca

doi:10.1016/0024-3205(91)90179-f

Cited by 19 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…115 The role of PAF in glomerular injury derives from studies in different experimental models of glomerulonephritis: increased glomerular production of PAF and improvement of the disease by a specific PAF receptor antagonist was observed in nephrotoxic nephritis, [116][117][118] acute serum sickness, 119 anti-Thy-1 glomerulonephritis, 120 and murine lupus nephritis. 121 In murine lupus nephritis, increased plasmatic and urinary levels of PAF correlated with proteinuria and renal histological abnormalities, 122 and in the same model, chronic administration of a PAF receptor antagonist reduced proteinuria and improved survival. 121 Other platelet secretory products that may alter glomerular permeability are endogenous polycationic macromolecules, platelet factor 4 (PF4), and b-thromboglobulin.…”

Section: Platelets In Glomerular Diseasesmentioning

confidence: 98%

Platelet Dysfunction in Renal Failure

Boccardo¹,

Remuzzi²,

Galbusera³

2004

Semin Thromb Hemost

Self Cite

412

287

View full text Add to dashboard Cite

Patients with end-stage renal disease suffer from complex hemostatic disorders. Uremic patients show a bleeding diathesis that is mainly due to abnormalities of primary hemostasis; in particular, platelet dysfunction and impaired platelet-vessel wall interaction. However, despite decreased platelet function, these patients have a high prevalence of cardiovascular and thrombotic complications. Platelet dysfunction in uremic patients is partially due to uremic toxins present in circulating blood. Dialysis improves platelet abnormalities and reduces, but does not eliminate, the risk of hemorrhage. Hemodialysis can even contribute to the bleeding through the continuous platelet activation induced by the interaction between blood and artificial surfaces. Thrombocytopenia, glomerular thrombosis, and thrombi in small arteries and glomerular capillaries are common pathological features in many renal diseases. Platelets are also involved directly in the pathogenesis of glomerular diseases through a variety of mechanisms, including release of active molecules, by enhancing immune complex deposition, and by altering glomerular permeability.

show abstract

Section: Platelets In Glomerular Diseasesmentioning

confidence: 98%

Platelet Dysfunction in Renal Failure

Boccardo¹,

Remuzzi²,

Galbusera³

2004

Semin Thromb Hemost

Self Cite

412

287

View full text Add to dashboard Cite

show abstract

“…[10][11][12] The modest Lignan precursor in lupus nephritis WF Clark et al has been associated with amelioration of the renal injury. [27][28][29][30] Initial studies in the MRL/lpr lupus mouse demonstrated that dietary supplementation with flaxseed was associated with renoprotection, with a decrease in proteinuria, a lengthening renal survival and amelioration of renal histologic changes. '8 These positive findings led to a flaxseed dosing study in man which demonstrated that patients could tolerate 15 and 30, but not 45 g of crushed flaxseed daily.19 This dosing study was associated with an improvement in renal function, as well as alteration in immune and lipid parameters.…”

Section: Introductionmentioning

confidence: 99%

A novel treatment for lupus nephritis: lignan precursor derived from flax

Clark

Muir²,

Westcott

et al. 2000

Lupus

View full text Add to dashboard Cite

show abstract

“…PAF acts through a specific receptor [19] and is considered to be a mediator of cell‐to‐cell communication on account of its role as an intercellular or intracellular messenger [15,20,21]. Increased levels of both circulating and urinary PAF have been observed in experimental and human lupus nephritis and correlated with the severity of proteinuria [22,23]. Moreover, a causative role for PAF in lupus glomerular injury has been suggested by the reduction of renal damage induced by PAF receptor blockade in murine SLE [24,25].…”

Section: Introductionmentioning

confidence: 99%

IL-10 stimulates production of platelet-activating factor by monocytes of patients with active systemic lupus erythematosus (SLE)

Bussolati

Rollino

Mariano³

et al. 2000

Clinical and Experimental Immunology

View full text Add to dashboard Cite

IL‐10 displays modulatory properties on the synthesis of platelet‐activating factor (PAF), a potent inflammatory mediator of vascular injury. Despite the fact that IL‐10 is considered to be an anti‐inflammatory cytokine, IL‐10 levels correlate with disease activity in SLE. Moreover, in SLE IL‐10 is unable to exert its immunosuppressive and anti‐inflammatory effects. We have investigated the ability of IL‐10 to stimulate PAF production from monocytes of SLE patients. Spontaneous and IL‐10‐stimulated PAF production by peripheral blood monocytes was measured in active (n = 13) and inactive (n = 14) SLE patients and in 15 normal control subjects. We observed that monocytes derived from patients with active SLE, but not from controls or inactive SLE, spontaneously produced significant amounts of PAF. Moreover, IL‐10 enhanced the synthesis of PAF from monocytes of active SLE patients only. IL‐10‐induced PAF production correlated with the severity of the disease and with the extent of proteinuria. These results indicate that IL‐10 only stimulates the synthesis of PAF from monocytes of SLE patients when immunologically active, suggesting that IL‐10 may possess a paradoxical proinflammatory effect in SLE by promoting the production of PAF, a secondary mediator of inflammation.

show abstract

Increased urinary excretion of platelet activating factor in mice with lupus nephritis

Cited by 19 publications

References 25 publications

Platelet Dysfunction in Renal Failure

Platelet Dysfunction in Renal Failure

A novel treatment for lupus nephritis: lignan precursor derived from flax

IL-10 stimulates production of platelet-activating factor by monocytes of patients with active systemic lupus erythematosus (SLE)

Contact Info

Product

Resources

About